NCT06170177 Study on the Quality of Life and Pathological State in Patients Who Underwent Radical Cystectomy
| NCT ID | NCT06170177 |
| Status | Recruiting |
| Phase | — |
| Sponsor | IRCCS San Raffaele |
| Condition | Muscle-Invasive Bladder Carcinoma |
| Study Type | OBSERVATIONAL |
| Enrollment | 4,000 participants |
| Start Date | 2013-02-04 |
| Primary Completion | 2063-02 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 4,000 participants in total. It began in 2013-02-04 with a primary completion date of 2063-02.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Observational study on the quality of life and pathological state of patients underwent radical cystectomy.
Eligibility Criteria
Inclusion Criteria: * subjects underwent radical cystectomy * \> 18 years old * Ability to read and sign the informed consent Exclusion Criteria: * Age \<18 years * Inability to read and sign the informed consent
Contact & Investigator
Francesco Montorsi, MD
PRINCIPAL INVESTIGATOR
IRCCS Ospedale San Raffaele
Frequently Asked Questions
Who can join the NCT06170177 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Muscle-Invasive Bladder Carcinoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06170177 currently recruiting?
Yes, NCT06170177 is actively recruiting participants. Contact the research team at montorsi.francesco@hsr.it for enrollment information.
Where is the NCT06170177 trial being conducted?
This trial is being conducted at Milan, Italy.
Who is sponsoring the NCT06170177 clinical trial?
NCT06170177 is sponsored by IRCCS San Raffaele. The principal investigator is Francesco Montorsi, MD at IRCCS Ospedale San Raffaele. The trial plans to enroll 4,000 participants.